ReviewFrontiers in pharmacology2025
Uncovering the role of microRNAs in esophageal cancer: from pathogenesis to clinical applications.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The possible role of sirtuins and MiRNAs in gastrointestinal cancers: special focus on Sirt1.Cancer cell international · 2026Review
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
- Dissecting the role of epigenetic regulation in oral squamous cell carcinoma microenvironment: mechanisms and therapeutics.Frontiers in immunology · 2026Review
- MicroRNA Enrichment and Docking-Based Evaluation of Ilomastat Targeting of MMP-2 in Esophageal Squamous Cell Carcinoma: Insights from a South African Cohort.Computational and structural biotechnology journal · 2026Article
- Bioinformatics analysis identifiesTranslational cancer research · 2025Article
- Visfatin facilitates esophageal cancer migration by suppressing miR‑3613‑5p expression and promoting VEZF1/VCAN production.Oncology reports · 2025Article
- MicroRNA- 103 as a novel potential biomarker of poor prognosis and durg resistance in solid tumours.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer (EC) presents substantial therapeutic challenges due to its high mortality rate and the tendency for diagnosis at advanced stages. Acknowledging the constraints of the existing current treatment paradigm, there is a pressing need for the development of innovative, targeted therapeutic strategies to surpass the current stagnation in survival rate improvements. Recently, microRNAs (miRNAs) have attracted significant attention for their capacity to regulate gene expression at the post-transcriptional level, thereby influencing various cellular processes. In this review, we provide a comprehensive analysis of the role of miRNAs in EC, emphasizing their mechanisms in tumorigenesis, their potential as diagnostic and prognostic biomarkers, and their influence on resistance to therapy. We elucidate how miRNAs modulate oncogenic pathways and tumor suppressor genes, influencing EC cell behavior and treatment outcomes. By integrating insights from genetic sequencing and molecular biology, we identify key miRNAs that promote or inhibit EC progression and treatment resistance. This review highlights critical need for an enhanced understanding of miRNAs in EC, advocating for their integration into therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.